Buy Ajanta Pharma; target of Rs 2028: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 2028 in its research report dated May 03, 2017.
June 08, 2017 / 07:03 PM IST
Motilal Oswal's research report on Ajanta Pharma
AJP posted in-line sales of INR 4.8b (est. of INR 4.7b). EBITDA margin of 35.9%, adjusted for forex loss accounting for mark-to-market, was significantly better than estimate of 33.8% due to a superior product mix. Higher depreciation on account of commercialization of the Guwahati facility and lower-than-expected other income led to PBT growing at a lower rate than EBITDA.
We remain positive on AJP, given its aggressive filings in the US and better-than-industry growth in India branded sales. We tweak FY18 estimates to factor in better EBITDA margin and a marginal fall in Africa sales. We maintain FY19 estimates and TP of 2,028 on 25x FY19E earnings. Reiterate Buy.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.